CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 77 enrolled
Drug / intervention
MRI of the prostatedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06244680
NCT06244680N/ACompleted
CompareCT.gov

Super-fast 3T Prostate MRI Using High Gradient Strength and Deep Learning: Initial Experience

University Hospital, Bonn·observational·Posted Feb 6, 2024·Updated Feb 6, 2024

In Brief

An observational study evaluating MRI of the prostate for Prostate Cancer. Completed, enrolled 77 participants across 1 site.

Detailed Summary

Recent developments in MRI techniques allow ultra-high gradient strength diffusion imaging and deep learning (DL) reconstruction in clinical routine. However, its usability in biparametric MRI (bpMRI) of the prostate has not been well studied. The aim is to establish a super-fast 3-minutes bpMRI protocol at 3 Tesla using high gradient strength and DL reconstruction and compare it against a full, multiparametric MRI (mpMRI) protocol.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedFeb 6, 2024
Enrollment StartNov 1, 2023
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.4 years ago

Interventions

MRI of the prostatedevice

Patients with suspicion for prostate cancer underwent mpMRI on a new 3-Tesla-MRI scanner with a maximum gradient strength of 200 mT/m, a slew rate of 200 T/m/s and DL reconstruction for image postprocessing.